TBPH
Theravance Biopharma, Inc.Healthcare$16.02
▼ Bearish
Mkt Cap: $824.9M|Float: 24.3M|SI: 21.2%|DTC: 5.5
Data as of market close Apr 2, 2026
IV Rank
100
IV Pctl
89%
HV 20d
27.8%
52W Range
$8-$21
ATR(14)
$0.54
Exp. Move
±10.5%
P/C Ratio
7.72
Earnings
May 7
GEX Negative
DEX Long
Net Put Premium
IV High
Max Pain Below
Exp. Move Wide
High Put/Call
TBPH Key Options Data
- IV Rank
- 100%
- Total GEX
- $-0.00B
- Total DEX
- $0.3M
- Max Pain
- $12.50
- Expected Move
- ±10.5%
- Put/Call OI
- 7.72
- Net Premium
- $-0.0M
- Spot Price
- $16.02
Gamma Exposure (GEX)
Delta Exposure (DEX)
Expected Move by Expiration
| Expiration | DTE | Expected Move | Move % | Lower | Upper |
|---|---|---|---|---|---|
| 2026-04-17 | 15 | ±$1.68 | ±10.5% | $14.35 | $17.70 |
| 2026-05-15 | 43 | ±$2.40 | ±15.0% | $13.62 | $18.42 |
| 2026-06-18 | 77 | ±$8.62 | ±53.8% | $7.40 | $24.65 |
| 2026-09-18 | 169 | ±$2.60 | ±16.2% | $13.42 | $18.62 |
| 2026-12-18 | 260 | ±$2.85 | ±17.8% | $13.17 | $18.87 |
| 2027-01-15 | 288 | ±$2.50 | ±15.6% | $13.52 | $18.52 |
Explore TBPH options data including implied volatility rankings, gamma and delta exposure, max pain levels, and expected price moves. AI-generated reports provide directional, income, and earnings analysis.